gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma

Ellinor Peerschke (*), Kenneth Stier (2), Xiaoyu Li (3,4), Evelyn Kandov (2), Elisa de Stanchina (5), Qing Chang (6), Yuquan Xiong (4), Katia Manova-Todorova (6), Ning Fan (6), Afsar Barlas (6), Berhane Ghebrehiwet (2) and Prasad S. Adusumilli (4)

1 Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 2 Departments of Medicine and Pathology, Stony Brook University, Stony Brook, New York, NY, United States, 3 Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China, 4 Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States, 5 Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY, United States, 6 Molecular Cytology Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, United States

Mesothelioma is an aggressive cancer of the serous membranes with poor prognosis despite combination therapy consisting of surgery, radiotherapy, and platinum-based chemotherapy. Targeted therapies, including immunotherapies, have reported limited success, suggesting the need for additional therapeutic targets. This study investigates a potential new therapeutic target, gC1qR/HABP1/p32 (gC1qR), which is overexpressed in all morphologic subtypes of mesothelioma. gC1qR is a complement receptor that is associated with several cellular functions, including cell proliferation and angiogenesis. In vitro and in vivo experiments were conducted to test the hypothesis that targeting gC1qR with a specific gC1qR monoclonal antibody 60.11 reduces mesothelioma tumor growth, using the biphasic mesothelioma cell line MSTO-211H (MSTO). In vitro studies demonstrate cell surface and extracellular gC1qR expression by MSTO cells, and a modest 25.3 ± 1.8% (n = 4) reduction in cell proliferation by the gC1qR blocking 60.11 antibody. This inhibition was specific for targeting the C1q binding domain of gC1qR at aa 76–93, as a separate monoclonal antibody 74.5.2, directed against amino acids 204–218, had no discernable effect. In vivo studies, using a murine orthotopic xenotransplant model, demonstrated an even greater reduction in MSTO tumor growth (50% inhibition) in mice treated with the 60.11 antibody compared to controls. Immunohistochemical studies of resected tumors revealed increased cellular apoptosis by caspase 3 and TUNEL staining, in 60.11 treated tumors compared to controls, as well as impaired angiogenesis by decreased CD31 staining. Taken together, these data identify gC1qR as a potential new therapeutic target against mesothelioma with both antiproliferative and antiangiogenic properties.

Keywords: mesothelioma, complement, gC1qR/HABP1/p32, monoclonal antibody therapy, therapeutic target
INTRODUCTION

Mesothelioma is an aggressive cancer of the serous membranes, typically those lining the pleural space (1, 2). It is chiefly caused by exposure to and inhalation of asbestos. Treatment outcomes continue to be poor, despite multimodal therapy consisting of surgery, chemotherapy, and radiation (3–5). An estimated 38,400 individuals die globally each year from mesothelioma (6), and the incidence is expected to rise in the US as a result of asbestos exposure following destruction of the World Trade Center in New York, NY in 2001 (7). Novel therapies, especially targeted therapies, are needed to improve treatment outcomes and reduce off-target side effects (8, 9).

The complement system is emerging as a novel target in cancer therapy. Complement is involved not only in shaping the inflammatory tumor microenvironment, but also in tumor growth and spread (10). In this regard, the complement component C1q is increasingly recognized as a tumor-promoting factor. It has been reported to enhance cancer cell adhesion, migration, proliferation, and angiogenesis (11–13).

We have identified gC1qR (also known as p32/HABP1) as the major cellular binding site for C1q (14). Marked upregulation of gC1qR expression has been observed in cancers of epithelial cell origin including breast, colon, and lung cancers (15, 16). In patients with breast cancer (17, 18), prostate cancer (19), and serous ovarian adenocarcinoma (20), as well as endometrial cell cancer (21), overexpression of gC1qR has been associated with poor prognosis. In addition, gC1qR is being considered as a potential molecular target for delivery of cytotoxic agents (22, 23) in breast cancer.

gC1qR, a multicompartamental cellular protein (24), with expression in mitochondria, the cytosol, and at the cell surface. In addition, gC1qR is cleaved from cell membrane for release into the extracellular milieu by enzymes such as the membrane-type metalloproteinase MT1MMP (25, 26). gC1qR shedding by cancer cells has been hypothesized to form a biochemical shield to protect malignant cells from complement mediated attack and produce inflammatory mediators to promote and enhance cancer metastasis (27). Interestingly, gC1qR has been described to exert both pro-proliferative and antiproliferative properties in cancer (24). Many cancer cells have been reported to express gC1qR with varying biological effects (11, 13, 28).

We recently described the overexpression of gC1qR in all mesothelioma subtypes, including epitheloid, sarcomatoid, and biphasic phenotypes (29). This finding suggests that gC1qR may represent a novel therapeutic target against mesothelioma. The present study tested this hypothesis in in vitro and in vivo experiments using a biphasic cultured human mesothelioma cell line, M5STO-211H (MSTO). The data demonstrate that targeting gC1qR with monoclonal antibody 60.11 reduces cell proliferation in vitro and tumor growth in vivo, associated with increased apoptosis and decreased angiogenesis, and provide proof of concept for further exploration of gC1qR directed therapy in mesothelioma.

METHODS

Materials

The following materials were purchased from the sources indicated: MSTO-211H biphasic mesothelioma cell line (MSTO; ATCC, Manassas, VA); RPMI 1640, 100× penicillin/streptomycin, and 0.05% trypsin-EDTA (GIBCO-Invitrogen, Grand Island, NY); heat-inactivated fetal bovine serum (FBS; HyClone, Logan, UT); coating buffer (CB) comprised of 35 mM sodium bicarbonate and 15 mM sodium carbonate, aqueous; tris-buffered saline (TBS) comprised of 20 mM tris-HCl, 150 mM sodium chloride, and 0.05% tween, aqueous; ChromPure human IgG Fc fragments (Jackson ImmunoResearch, West Grove, PA); para-nitrophenyl phosphate (pNPP; Pierce, Rockford, IL); and Dulbecco’s PBS (Mediatech Inc., Manassas, VA).

Monoclonal Antibodies (mAbs)

mAbs to gC1qR were generated as described (30). The 60.11 therapeutic antibody is directed against the C1q binding domain of gC1qR, amino acids 76–93. mAb 74.5.2 recognizes amino acids 204–218, which constitutes the binding site for high molecular weight kininogen. AlexaFluor 488-conjugated secondary antibodies (Invitrogen, Carlsbad, CA) and non-immune mouse IgG MOPC 21 (Sigma-Aldrich) were purchased.

Cell Culture

MSTO cells were cultured in RPMI supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin, in T175 culture flasks. Cultures were maintained at 37°C, 100% humidity, 5% CO₂, and subcultured when cells reached ~90% confluence.

Recombinant gC1qR

The strategy for the construction of a plasmid containing the full-length (mature form or wild type, WT) and purification of the glutathione-S-transferase (GST)–gC1qR fusion products has been described in detail (14). The GST-gC1qR fusion product is cleaved by thrombin (3.2 µg/ml) and the GST-free gC1qR protein is purified on fast protein liquid chromatography (FPLC, Pharmacia) using a Mono-Q ion exchange column. The single peak containing the gC1qR pool, concentrated to 1–2 mg/ml, and stored at −80°C in the presence of 50 nM PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone), a specific thrombin inhibitor (Sigma Aldrich).

Detection of Soluble gC1qR

A qualitative direct ELISA was used to evaluate the presence of soluble gC1qR in MSTO culture medium. MSTO were seeded at 50,000 cells per well and grown for 48 h. Culture supernatants were harvested and centrifuged to remove cellular debris, diluted 1:1 with CB, and incubated in a high-binding microtiter well-plate for 1 h at ambient temperature. Wells were blocked with 1% heat-inactivated bovine serum albumin (BSA) in TBS, 10 min. Immobilized gC1qR was detected with biotinylated immunoaffinity purified polyclonal antibody to gC1qR peptide (144–155) conjugated to alkaline phosphatase, and pNPP substrate. Absorbance was measured at 405 nm.
Soluble gC1qR in pleural fluid from patients with advanced malignant pleural mesothelioma was quantified using a commercial, quantitative human gC1qR ELISA kit (Hycult, Netherlands) (26). Deidentified patient samples (n = 22) were evaluated according to manufacturer instruction and in compliance with Memorial Sloan Kettering IRB approved protocols (#16-1547).

**Immunofluorescence Microscopy**

MSTO cells were seeded in 24-well-tissue culture-treated plates (50,000 cells per well) and grown to near-confluence. Cells were fixed (10 min) in 1% paraformaldehyde. Wells were blocked with 1% BSA and 1 µg/ml Fc fragments (30 min). gC1qR expression was examined by incubation (30 min) with anti-gC1qR mAb 60.11 (5 µg per well) followed by 30 min incubation with AlexaFluor 488-conjugated goat anti-mouse secondary antibody (5 µg per well). Staining with non-immune rabbit IgG (NIRG) and AlexaFluor 488-conjugated goat anti-rabbit secondary antibody served as a negative control. DAPI (0.2 µg per well) was used as a nuclear counterstain. Images were obtained using an Evos FL Imaging System at 10× magnification and normalized for background brightness. Additional brightness and contrast adjustments were applied uniformly to each image via Adobe Photoshop CS6.

**Flow Cytometry**

MSTO cells were detached from culture plates by incubation (30 min, room temperature) with 0.05% trypsin–0.01% EDTA in 0.01 M TBS, centrifuged (800 g, 5 min) and suspended using 10 mM EDTA in PBS, pH 7.4. Cellular Fc receptors were blocked with 5 µg Fc fragments per 500,000 cells. gC1qR expression was detected with mouse anti-gC1qR mAb 74.5.2, and MOPC 21, as negative control. The gC1qR 74.5.2 antibody was preferred for flow cytometry studies as it produced greater staining of cells than the 60.11 antibody. Primary antibodies were visualized with AlexaFluor 488-conjugated goat pAb to mouse IgG. Unstained cells were used an additional negative control. Cells were fixed in 1% paraformaldehyde. All reagents were diluted in DPBS. Fluorescence was determined using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA).

**MSTO Cell Adhesion Assay**

Cells were cultured as described above and imaged at 24-h intervals via compound light microscopy (10× magnification) with a PAXcam 3 microscope camera and Pax-it 11 software (Paxcam, Villa Park, IL). MSTO cells were seeded at 50,000 cells/well, in the presence or absence of 5 µg/ml recombinant gC1qR. To evaluate the effect of immobilized gC1qR on cell adhesion, microtiter wells were incubated overnight (37°C) with 20 µg/ml recombinant gC1qR in CB and rinsed with PBS before exposure to cells.

**MSTO Cell Proliferation Assay**

MSTO cells were seeded in 24-well-cell culture plates at 50,000 cells per well and allowed to adhere overnight. Cultures were subsequently treated with 10 µg/ml anti-gC1qR mAb 60.11 or 74.5.2. Untreated cultures were used as controls. Cell proliferation was determined at 24 h intervals. At the desired times, cells were removed from culture wells using 0.05% trypsin-EDTA, stained with trypan blue dye, and counted using a hemocytometer. Trypan blue positive cells were excluded from the count.

**Orthotopic Pleural Mesothelioma Mouse Model**

All procedures were performed under approved Institutional Animal Care and Use Committee protocols. Female severe combined immunodeficiency gamma mice (NSG (NOD, scid, gamma), Jackson Laboratories), 6–8 weeks old, were anesthetized using inhaled isoflurane and oxygen. Direct intrapleural injection of 1 × 10⁶ GFP-Firefly Luciferase expressing MSTO-211H cells in 200 µl serum-free media was administered to establish orthotopic malignant pleural mesothelioma tumors via a right thoracic incision, as previously described (31–33). For this proof of concept study, mice were divided into two treatment groups: vehicle (n = 10), and 60.11 antibody treatment (n = 10) (100 mg/kg, administered twice weekly by intraperitoneal injection beginning on day 8 after tumor implantation). Intrapleitoneal injection of antibody was chosen over the intravenous route, as it allowed for the administration of greater fluid volume, which was required to reach the desired therapeutic antibody dose. Clinical assessments of animal distress (weight loss, disruption of locomotor coordination, hunching, lack of grooming, lethargy) were made and recorded daily to assess toxicity.

Tumor burden was measured beginning on day 8 after tumor implantation, and at regular intervals until day 23 using quantitative bioluminescence imaging (BLI). Mice were imaged with the Xenogen IVIS 100 Imaging System, 20 min following injection of a single intraperitoneal dose of 150 mg/kg D-Luciferin. Images were acquired for 5–30 s depending on signal strength. BLI data were analyzed using Living Image 2.60 software and BLI signal reported as total flux (Photons/s). Due to high tumor burden observed in the control group, the experiment was terminated at day 23. At time of sacrifice, blood was collected for cell counts and measurement of serum 60.11 antibody levels using a direct ELISA assay with immobilized recombinant gC1qR. Tumors were removed, fixed and processed for histologic (hematoxylin and eosin staining) and immunohistochemical evaluation.

**Immunohistochemical Analysis**

Tissue processing and immunohistochemical analysis was performed by the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center as previously described (31, 32). In brief, tissues were fixed in 4% formaldehyde and processed by paraffin embedding using a tissue processor (Leica ASP6025). Five micrometer sections were obtained and applied to superfrost plus slides. Immunohistochemical detection of Ki67, Cleaved Caspase 3, TUNEL, and CD31 was performed using a Discovery XT processor (Ventana Medical Systems). Slides were counterstained with hematoxylin and cover-slipped with Permount (Fisher Scientific).
Ki-67
The Discovery XT autostainer was programmed to incubate slides with primary rabbit polyclonal Ki-67 antibody (Abcam, catalog # ab16667) at 1 µg/ml for 4 h, followed by incubation with secondary antibody (biotinylated goat anti-rabbit IgG; Vector labs) at a concentration of 5.75 µg/ml for 30 min. Blocker D, Streptavidin-HRP, and DAB detection kit (Ventana Medical Systems) were used according to manufacturer instructions.

Cleaved Caspase 3
A rabbit polyclonal Cleaved Caspase 3 antibody (Cell Signaling, catalog # 9661) was used at 0.1 µg/ml concentration. Slides were incubated in the Discovery XT autostainer for 3 h. Incubation with secondary antibody (biotinylated goat anti-rabbit IgG; Vector labs) at a concentration of 5.75 µg/ml occurred for 20 min. Blocker D, Streptavidin-HRP, and DAB detection kit (Ventana Medical Systems) were used according to manufacturer instructions.

TUNEL
Terminal deoxynucleotidyl dUTP nick end labeling (TUNEL) analysis was done as follows. Slides were manually deparaffinized in xylene, rehydrated in a series of alcohol dilutions (100, 95, and 70%) and tap water, and placed into the autostainer, where tissue sections were treated with Proteinase K (20 µg/ml in PBS) for 8 min, and incubated with endogenous biotin blocking kit (Roche) for 12 min, followed by incubation with labeling mix: TdT (Roche, 1,000 U/ml) and biotin-dUTP (Roche, 4.5 nmol/ml) for 2 h. Detection was performed with Streptavidin-HRP and DAB detection kit (Ventana Medical Systems) according to the manufacturer’s instruction.

CD31
Primary antibody, a rat anti-mouse CD31 antibody (Dianova, catalog # DIA-310) was used at 2 µg/ml. Slides were incubated in the autostainer for 6 h, followed by exposure to biotinylated rabbit anti-rat IgG (Vector, 1:200 dilution) for 60 min. Blocker D, Streptavidin-HRP, and DAB detection kit (Ventana Medical Systems) were used according to the manufacturer’s instructions.
Quantitative Analysis of Immunohistochemical Staining

Quantitative analysis of immunohistochemical staining was performed of images generated by a slide scanner (Panoramic Flash 250, 3DHistech, Hungary) using Image J software.

Statistical Analysis

Data were analyzed with Student's t-test as applicable, and p < 0.05 were considered statistically significant. All statistical analysis, calculations, and graphing were performed in Excel (Microsoft, Redmond, WA).

RESULTS

In vitro Studies

In order to assess the effect of anti-gC1qR therapy on MSTO cell proliferation, in vitro studies first evaluated the expression of the target antigen by MSTO cells. Expression of gC1qR by MSTO cells was demonstrated by immunofluorescence microscopy (Figure 1A) and flow cytometry (Figure 1B). In addition, soluble gC1qR was detected in culture supernatants of MSTO cells. Progressively increasing amounts of gC1qR were shed into the cell culture medium over a 72 h time course (Figure 2). Soluble gC1qR was found also in vivo, in 10 of 22 pleural fluids from patients with malignant pleural mesothelioma, with a mean concentration of 1.11 ± 0.57 ng/ml (n = 10). Interestingly, soluble gC1qR and immobilized gC1qR, enhanced MSTO cell adhesion in culture (Figure 3). Cell proliferation was reduced 25.3 ± 1.8% (n = 4) by targeting gC1qR with mAb (60.11) (Figure 4). This inhibition was specific for mAb 60.11, directed against amino terminal amino acids 76–93, representing the C1q binding domain (28). As illustrated in Figure 4, gC1qR mAb 74.5.2, directed against aa 204–218, had a negligible effect (2.9 ± 2.2% inhibition).

In vivo Studies

An orthotopic mouse model of malignant pleural mesothelioma was used to evaluate gC1qR blockade with mAb 60.11 on MSTO cell proliferation. The data are summarized in Table 1. Animals...
cells with significant areas of necrosis. Immunohistochemical analysis by H&E staining. Tumors consisted of densely packed MSTO cells from control mice, no histologic differences were appreciated. Tumor burden from treated mice was macroscopically smaller than those excised from control at baseline. However, the decrease in tumor development compared to vehicle control. No difference in the tumor cell proliferation index (Ki67) was noted between treatment groups. Interestingly, 60.11 therapy was associated with decreased tumor CD31 staining, suggesting decreased angiogenesis. In addition, the CD31 positive vessels in tumors of 60.11 treated animals appeared generally small and poorly developed. 

**DISCUSSION**

The data provide proof of concept that targeting the complement receptor, gC1qR, at the C1q binding site, may provide a potential novel therapeutic strategy in mesothelioma. The present study was developed based on our recent observation that gC1qR is overexpressed in malignant pleural mesothelioma (29), and reports from breast and lung cancer models, indicating decreased tumor cell proliferation (34–36) using gC1qR-targeted strategies. In vitro studies with the biphasic mesothelioma cell line MSTO demonstrate the presence of targetable gC1qR on the cell surface and in the extracellular milieu. Interestingly, extracellular gC1qR enhanced MSTO cell adhesion and proliferation in vitro, and may have similar direct effects in vivo. Additional postulated roles for extracellular gC1qR include shielding of the tumor from classical complement mediated attack, and activation of the kallikrein system with bradykinin generation and vascular leakage that may contribute to tumor metastasis (27).

The ability of tumor cells to adhere to tissue surfaces is a key element in metastasis formation (37). Thus, the enhanced ability of MSTO cells to adhere to immobilized gC1qR supports the hypothesis that gC1qR in the tumor microenvironment may contribute to tumor progression via autocrine or paracrine effects. This observation requires further exploration.

**TABLE 1** Targeted gC1qR (60.11) treatment reduces MSTO-211H tumor cell growth in an orthotopic murine xenotransplant model.

| Treatment Group | Vehicle Control | 60.11 Treatment | p |
|-----------------|-----------------|-----------------|---|
| **Tumor Burden**<br>(BLI, Total Flux, × 10<sup>7</sup>)<br>**Baseline**<br>Vehicle Control | 2.1 ± 1.0 | 2.4 ± 1.4 | 0.635 |
| **Week 1**<br>Vehiicle Control | 18.8 ± 6.1 | 9.6 ± 3.6 | 0.0006 |
| **Week 2**<br>Vehiicle Control | 61.1 ± 25.6 | 34.6 ± 19.6 | 0.018 |

BLI, Bioluminescence Imaging.

**FIGURE 4** Antibodies directed against the C1q binding site of gC1qR decrease mesothelioma cell proliferation. MSTO-211H cells was treated with 10 ng/mL monoclonal anti gC1qR antibody mAb 60.11 directed against the high molecular weight kininogen binding domain (aa 204–218). Cell proliferation was determined via hemocytometer cell counts of viable cells after 96 h incubation. Error bars represent mean cell population ± standard deviation. n = 2 separate experiments performed in duplicate. *Significant difference from control at p = 1.33 × 10<sup>−5</sup>.

**TABLE 2** Effect of 60.11 therapy on mouse weight and blood cell counts.

| Treatment Groups | Weight (g) | Cell Count |
|------------------|-----------|------------|
| Vehicle          | 23.0 ± 1.16 | RBC (10<sup>6</sup>/µl) 9.01 ± 0.70, Hgb (g/dl) 15.01 ± 1.15, HCT (%) 43.54 ± 3.14, MCV (fl) 48.33 ± 0.61, Neutrophils (10<sup>3</sup>/µl) 4.57 ± 0.92, Lymphocytes (10<sup>3</sup>/µl) 0.032 ± 0.019, Monocytes (10<sup>3</sup>/µl) 0.292 ± 0.134, Eosinophils (10<sup>3</sup>/µl) 0.125 ± 0.067, Basophils (10<sup>3</sup>/µl) 0.06 ± 0.013 | 8.58 ± 0.63, 14.23 ± 1.01, 41.91 ± 2.50, 48.92 ± 1.13, 3.24 ± 0.91*, 0.014 ± 0.014*, 0.258 ± 0.10, 0.137 ± 0.081, 0.02 ± 0.004 |
| 60.11 treatment  | 23.5 ± 1.08 | |

*p < 0.05.

treated with the 60.11 antibody showed an approximately 50% reduction in tumor development compared to vehicle control. Serum 60.11 antibody concentrations measured on day of sacrifice ranged from 30 to 50 µg/ml. 60.11 therapy was not associated with clinical changes such as weight loss (Table 2), disruption of locomotor coordination, hunching, and lack of grooming or lethargy. Comparison of peripheral blood cell counts showed no change in RBC and platelet counts between treatment groups, but a modest decrease in WBC counts, predominantly associated with a decrease in neutrophils in 60.11 treated mice, was observed (Table 2).

**Figure 5** shows representative images of tumors resected from control and 60.11 treated mice. Although tumors from 60.11 treated mice were macroscopically smaller than those excised from control mice, no histologic differences were appreciated by H&E staining. Tumors consisted of densely packed MSTO cells with significant areas of necrosis. Immunohistochemical analysis (Figure 6) revealed an increase in early and late apoptosis markers, cleaved caspase 3, and TUNEL, respectively, in tumors from 60.11 treated mice compared to controls. No difference in the tumor cell proliferation index (Ki67) was noted between treatment groups. Interestingly, 60.11 therapy was associated with decreased tumor CD31 staining, suggesting decreased angiogenesis.

The expanded ability of MSTO cells to adhere to immobilized gC1qR supports the hypothesis that gC1qR in the tumor microenvironment may contribute to tumor progression via autocrine or paracrine effects. This observation requires further exploration.
FIGURE 5 | MSTO-211H tumors resected from control and 60.11 treated mice are histologically similar. Representative histologic (10 ×) images of tumors stained with hematoxylin and eosin show tightly packed MSTO-211H cells and areas of necrosis. No histologic differences in tumor morphology were apparent between control and treatment groups.

FIGURE 6 | Therapy with 60.11 increases apoptosis and reduces neovascularization in mesothelioma. Representative histologic images (20 × original magnification) of tumors obtained from control and 60.11 treated mice stained with cleaved caspase 3, TUNEL, CD31, and Ki 76 are shown. Positive immunohistochemical reactivity is indicated by brown stain. Quantitative analysis of staining intensity is shown in the inset. N, number of microscopic fields selected for analysis.

Study, since levels of soluble gC1qR, previously detected in blood and body fluids (26), as well as those noted in pleural effusions from patients with MPM, are significantly lower than those found to enhance cell proliferation in vitro. Concentrations in the tumor microenvironment, however, are likely different, and greater in the microenvironment immediately adjacent to the tumor.

Targeting gC1qR, at the C1q binding site with mAb 60.11, reduced MSTO cell proliferation in vitro, and to a greater extent in vivo, using a clinically relevant orthotopic
pleural mesothelioma mouse model. This model resembles pleural mesothelioma in humans with associated extensive lymphangiogenesis, regional invasion, and shortened survival (31). Data from immunohistochemical studies comparing tumors from 60.11 treated and control mice reveal that inhibition of in vivo mesothelioma tumor growth is associated with both increased apoptosis and decreased angiogenesis.

One of the major ligands of gC1qR is C1q (14). The role of C1q in tumorigenesis is multifactorial. C1q is thought to promote tumor growth in part through its support of neovascularization (12). Indeed, in the present study, immunohistochemical analysis of tumors treated with 60.11 therapy demonstrate a decreased and abnormal microvasculature. Since mAb 60.11 is directed specifically against the C1q binding site of gC1qR, these findings support the hypothesis that gC1qR—C1q interactions in the tumor cell microenvironment contribute to mesothelioma tumor growth. Interestingly, recent immunohistochemical studies report the presence of C1q in mesothelioma (38). The observed anti-angiogenic effect of 60.11 therapy likely contributes to the overall in vivo effect of 60.11 therapy. This observation illustrates the complexity of tumor growth in vivo, and demonstrates that cell proliferation in vitro is not directly comparable to tumor growth in vivo.

Therapy with 60.11 was not associated with clinically discernable toxicity. Animal weights were similar between treatment and control groups. No difference in animal appearance, habitus or behavior was noted. However, a statistically significant decrease in total WBC was observed in the treatment group, which was attributed predominantly to a decrease in neutrophil count. Lymphocyte counts in the NSG mice are extremely low and differences between groups are therefore difficult to interpret. Given the observed significant anti-mesothelioma effect of 60.11 therapy, further exploration of both its therapeutic potential and toxicity profile are indicated.

The paucity of effective therapies for mesothelioma, including the limited success of mesothelin targeted therapy, immune checkpoint blockade, anti-angiogenesis therapies, and neoantigen based vaccines (39), necessitate the development of additional therapeutic strategies. This exploratory study provides the first in vivo proof of concept that targeting gC1qR at the C1q binding site can significantly reduce mesothelioma tumor burden by increasing tumor cell apoptosis and decreasing tumor angiogenesis. The study is limited by use of a single cell line and a single anti gC1qR targeting strategy. However, current results support further exploration of gC1qR as a potential new therapeutic target. Investigation of additional gC1qR targeting antibodies may further maximize treatment efficacy. For example, the 74.5.2 antibody, which has no effect on cell proliferation, is a potent inhibitor of vascular permeability, blocking the binding of high molecular weight kininogen to vascular endothelial cells (40). In addition, combining gC1qR targeted therapy with chemotherapy or other targeted therapies should be evaluated in further preclinical studies.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board/Privacy Board (FWA00004998). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. The animal study was reviewed and approved by Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center (protocol no. 04-03-009).

AUTHOR CONTRIBUTIONS

EP, BG, and PA designed the study, supervised experiments, analyzed data, and wrote the manuscript. ES, QC, and YX conducted the in vivo studies. KM-T, NF, and AB performed immunohistochemical analyses. KS and EK performed in vitro studies. All authors participated in data review and review of the manuscript.

FUNDING

This work was supported by the Mesothelioma Applied Research Foundation (Award No. 549976), grants from the National Institutes of Health (P30 CA008748, R01 CA236615-01, and R01 CA235667), the National Institute of Allergy and Infectious Diseases (RO1 AI 060866 and RO1 AI-084178), the U.S. Department of Defense (BC132124, LC160212, CA170630, and CA180889), the Batishwa Fellowship, the Comedy vs. Cancer Award, the Druckenmiller Center for Lung Cancer Research Fellowship, the Emerson Collective Cancer Research Fund, the Esophageal Cancer Education Fund, the Memorial Sloan Kettering Technology Development Fund, the Miner Fund for Mesothelioma Research, the Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center, and the Simons Summer Research Program funded by the Simons Foundation.

REFERENCES

1. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. (1998) 157:1666–80. doi: 10.1164/ajrcm.157.5.9

2. Adusumilli PS. Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma. Cancer. (2014) 120:3268–71. doi: 10.1002/cncr.28883

3. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy
14. Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EIB. The isolation, purification, and characterization of the dust/smoke aerosol that settled east of the World Trade Center (WTC) in lower Manhattan after the collapse of the WTC on September 11, 2001. Environ Health Perspect. (2002) 110:703–10. doi: 10.1289/ehp.0211070

15. Courtzellis I, Rafai S. The dual role of complement in cancer and its implication in anti-tumor therapy. Ann Transl Med. (2016) 4:265. doi: 10.21037/atm.2016.06.26

16. Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarnera C, et al. Ctq acts in the tumor microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. (2016) 7:10346. doi: 10.1038/ncomms10346

17. Bossi F, Tripodo C, Ruzzi L, Bulla R, Agostinis C, Guarnera C, et al. Ctq as a unique player in angiogenesis with therapeutic implication in wound healing. Proc Natl Acad Sci U S A. (2014) 111:4209–14. doi: 10.1073/pnas.1311961111

18. Ghebrehiwet B, Hosszu KK, Valentino A, Peerschke EIB. The Ctq family of proteins: insights into the emerging non-traditional functions. Front Immunol. (2012) 3:52. doi: 10.3389/fimmu.2012.00052

19. Ghebrehiwet B, Lim BL, Peerschke EIB, Willis AC, Reid KBM. Isolation, cDNA cloning, and overexpression of a 33-kDa cell surface glycoprotein that binds to the globular heads of C1q. J Exp Med. (1994) 179:1809–21. doi: 10.1083/jem.179.6.1809

20. Kubinstejn DB, Stortchevoi A, Boosalis M, Ashfaq R, Ghebrehiwet B, Peerschke EI, et al. Receptor for the globular heads of C1q (ctq-R, p33, hyaluronan binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer. (2004) 110:741–50. doi: 10.1002/ijc.20105

21. Dembitzer FR, Kinoshita Y, Burstein D, Phelps RG, Beasley MB, Garcia R, et al. CtqR expression in normal and pathologic human tissues: insights into the emerging non-traditional roles of C1q family of proteins: insights into the emerging non-traditional functions. Front Immunol. (2012) 3:52. doi: 10.3389/fimmu.2012.00052

22. Dembitzer FR, Kinoshita Y, Burstein D, Phelps RG, Beasley MB, Garcia R, et al. CtqR expression in normal and pathologic human tissues: insights into the emerging non-traditional functions. Front Immunol. (2012) 3:52. doi: 10.3389/fimmu.2012.00052

23. Chen YB, Jiang CT, Zhang GQ, Wang JS, Pang D. Increased expression of hyaluronic acid binding protein 1 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. (2009) 100:382–6. doi: 10.1002/jso.21329

24. Jiang Y, Wu H, Liu J, Chen Y, Xie J, Zhao Y, et al. Increased breast cancer risk with HABP1/p32/cG1qR genetic polymorphism rs2285747 and its upregulation in northern Chinese women. Oncotarget. (2017) 8:13932–41. doi: 10.18632/oncotarget.14737

25. Amamoto R, Yagi M, Song Y, Oda Y, Tsuneyoshi M, Naito S, et al. Myocardial p32/C1qBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy. Cancer Sci. (2011) 102:639–47. doi: 10.1111/j.1349-7006.2010.01188.x

26. Yu G, Wang J. Significance of hyaluronan binding protein (HABP1/P32/cG1qR) expression in advanced serous ovarian cancer patients. Exp Mol Pathol. (2013) 94:210–5. doi: 10.1016/j.yexmp.2012.06.007

27. Zhao J, Liu T, Yu G, Wang J. Overexpression of HABP1 correlated with clinicopathological characteristics and unfavorable prognosis in endometrial cancer. Tumour Biol. (2015) 36:1299–306. doi: 10.1007/s13277-014-2761-8

28. Saha P, Datta K. Multifunction, multicompartimental hyaluronan-binding protein 1 (HABP1/p32/cG1qR: implication in cancer progression and metastasis. Oncotarget. (2018) 9:17078–807. doi: 10.18632/oncotarget.24808

29. Rozanov DV, Ghebrehiwet B, Postnova TI, Eichinger A, Deryugina EI, Strongin AY. The hemopexin-like C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, cG1qR. J Biol Chem. (2002) 277:9318–25. doi: 10.1074/jbc.M111.711200

30. Peerschke EIB, Brandwijk R, Dembitzer FR, Kinoshita Y, Ghebrehiwet B. Soluble cG1qR in blood and body fluids: examination in a pancreatic cancer patient cohort. Int J Cancer Res Mol Med. (2016) 1:10. doi: 10.19666/2381-3318.110

31. Peerschke EIB, Ghebrehiwet B, cC1qR/CR and cG1qR/p33: Observations in cancer. Mol Immunol. (2014) 61:100–9. doi: 10.1016/j.molimm.2014.06.011

32. Ghebrehiwet B, Jesty J, Xu S, Vinayagasundaram R, Vinayagasundaram U, Ji Y, et al. Structure-function studies using deletion mutants identify domains of cG1qR/p33 as potential therapeutic targets for vascular permeability and inflammation. Front Immunol. (2011) 2:58. doi: 10.3389/fimmu.2011.00058

33. Li X, Eguchi T, Aly RG, Chintala NK, Tan KS, Zauderer, et al. C1q acts in the tumor microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. (2016) 7:10346. doi: 10.1038/ncomms10346

34. Kandov E, Kaur A, Kishore U, Ji P, Williams J, Peerschke EIB, et al. Receptor for the globular heads of C1q, using a C-terminal domain of membrane type 1 matrix metalloproteinase regulates proteolysis of a multifunctional protein, cG1qR. J Biol Chem. (2002) 277:9318–25. doi: 10.1074/jbc.M111.711200

35. Kim KB, Yi JS, Nguyen N, Lee JH, Kwon YC, Ahn BY, et al. Cell-surface protein that binds to the globular “heads” of C1Q, using monoclonal antibodies and synthetic peptides. Hybridoma. (1996) 15:333–42. doi: 10.1089/bhy.1996.15.333

36. Servais EL, Suzuki K, Colovos C, Bordon J, Peerschke EI, Rodriguez L, Sima C, Fleisher M, et al. An in vivo platform for tumor biomarker assessment. PLoS One. (2011) 6:e26722. doi: 10.1371/journal.pone.0026722

37. Servais EL, Colovos C, Rodriguez L, Bograd A, Nitisara J, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelial pleural mesothelioma patients. Clin Cancer Res. (2012) 18:2478–89. doi: 10.1158/1078-0432.CCR-11-2614

38. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. (2014) 6:261ra51. doi: 10.1126/scitranslmed.3001162

39. Kandov E, Kaur A, Kishore U, Ji P, Williams J, Peerschke EI, et al. Ctq and Ctq receptors (cG1qR and cC1qR) as potential novel targets for therapy against breast cancer. Curr Trends Immunol. (2018) 19:59–76. Available online at: https://www.scopus.com/inward/record.uri?eid=2-s2.0-8506216684&partnerID=40&md5= 7c8d57967cb5d34d8d116af75f73c4557

40. Kim KB, Yi JS, Nguyen N, Lee JH, Kwon YC, Ahn BY, et al. Cell-surface receptor for complement component C1q (cG1qR) is a key regulator for lamellipodia formation and cancer metastasis. J Biol Chem. (2011) 286:23093–101. doi: 10.1074/jbc.M111.233304
36. Kim B-C, Hwang H-J, An H-T, Lee H, Park JS, Hong J, et al. Antibody neutralization of cell-surface gC1qR/HABP1/SF2-p32 prevents lamellipodia formation and tumorigenesis. *Oncotarget*. (2016) 7:49972–85. doi: 10.18632/oncotarget.10267

37. Varani J, Lovett EJ, Elgebaly S, Lundy J, Ward PA. In vitro and in vivo adherence of tumor cell variants correlated with tumor formation. *Am J Pathol.* (1980) 101:345–52.

38. Agostinis C, Vidergar R, Belmonte B, Mangogna A, Amadio L, Geri P, et al. Complement protein C1q binds to hyaluronic acid in the malignant pleural mesothelioma microenvironment and promotes tumor growth. *Front Immunol.* (2017) 8:1559. doi: 10.3389/fimmu.2017.01559

39. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, et al. Scientific advances and new frontiers in mesothelioma therapeutics. *J Thorac Oncol.* (2018) 13:1269–83. doi: 10.1016/j.jtho.2018.06.011

40. Fandaros M, Ong CL, Rubenstein DA, Joseph K, Kaplan AP, Yin W, et al. Angioedema and shear stress modulate endothelial permeability through gC1qR. *FASEB J.* (2019) 33(Suppl 1):542.15.

**Conflict of Interest:** EP and BG receive royalty income from the commercialization of gC1qR antibodies, including 60.11, and hold a licensed patent for the use of gC1qR antibodies. PA has received research funding from ATARA Biotherapeutics and OSE Immunotherapies.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.